Physician profile
Emre Koca
NPI 1508271701
$1,102.22
in general payments reported to CMS, 2019-2025
25 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $217 · 2021: $11.92 · 2023: $184 · 2024: $88.27 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $359 · Education: $35.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $359.48 |
| Education | $35.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $128.90 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $127.50 | 2019-2023 | |
| Eusa Pharma (US) LLC | $108.42 | 2020 | |
| Lilly USA, LLC | $93.87 | 2019 | |
| Amgen INC. | $77.68 | 2019-2023 | Blincyto |
| Pfizer INC. | $64.80 | 2019-2020 | |
| Genentech USA, INC. | $57.21 | 2025 | Itovebi, Venclexta |
| Eisai INC. | $55.81 | 2023-2024 | |
| Celgene Corporation | $41.16 | 2019 | |
| Astellas Pharma US INC | $36.04 | 2019-2025 | Vyloy |
| Aveo Pharmaceuticals, INC. | $35.00 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $33.48 | 2019 | |
| Rigel Pharmaceuticals, INC. | $32.29 | 2019 | |
| Incyte Corporation | $31.93 | 2020 | |
| Agios Pharmaceuticals, INC. | $29.25 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $21.32 | 2024 | Lorbrena, Braftovi, Mektovi |
| Kite Pharma, INC. | $19.43 | 2023 | |
| Daiichi Sankyo INC. | $18.86 | 2024 | Enhertu |
| Smith+Nephew, INC. | $18.16 | 2019 | |
| Abbvie INC. | $16.02 | 2025 | |
| Stemline Therapeutics INC. | $14.85 | 2024 | Orserdu |
| Amag Pharmaceuticals, INC. | $14.18 | 2019 | |
| Seagen INC. | $14.14 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emre Koca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.